Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
作者： J. B. Auliac , C. Fournier , C. Audigier Valette , M. Perol , A. Bizieux
DOI: 10.1007/S11523-015-0387-4
关键词:
摘要: Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors (RECIST) progression epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. The aim this multicenter observational retrospective study was to assess the frequency practice and its impact on overall survival (OS). analysis included advanced EGFR-mutated NSCLC patients treated with TKI who experienced RECIST between June 2010 July 2012. Among 123 (67 ± 12.7 years, women: 69 %, non smokers: 68 PS 0–1: 87 %), 40.6 % continued therapy progression. There no difference did not continue respect progression-free (PFS1: 10.5 versus 9.5 months, p = 0.4). Overall (OS) showed non-significant trend favor continuing (33.0 vs. 21.2 0.054). Progressions were significantly less symptomatic group than discontinuation (18 37 1 (HR 4.33, 95 %CI: 2.21-8.47, 0.001), >1 one metastatic site 1.96, 1.06-3.61, 0.02), brain metastasis 1.75, 1.08-2.84, 0.02) at diagnosis, towards higher risk death cases 1.62, 0.98-2.67, 0.056 ). In multivariate only 6.27, 2.97-13.25, 0.00001) 2.54, 1.24-5.21, diagnosis remained significant. This suggests that under certain circumstances, is an acceptable option
springer.com
sci-hub.se 参考文章(27)
Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson, Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors Lung Cancer. ,vol. 79, pp. 283- 288 ,(2013) , 10.1016/J.LUNGCAN.2012.11.007
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou, Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International Journal of Cancer. ,vol. 131, ,(2012) , 10.1002/IJC.27396
A. B. Cortot, P. A. Janne, Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas European Respiratory Review. ,vol. 23, pp. 356- 366 ,(2014) , 10.1183/09059180.00004614
K. Nishino, F. Imamura, S. Morita, M. Mori, K. Komuta, T. Kijima, Y. Namba, T. Kumagai, S. Yamamoto, I. Tachibana, Y. Nakazawa, J. Uchida, S. Minami, R. Takahashi, Y. Yano, T. Okuyama, A. Kumanogoh, A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment Lung Cancer. ,vol. 82, pp. 299- 304 ,(2013) , 10.1016/J.LUNGCAN.2013.08.009
Jin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, Xu-Chao Zhang, Qing Zhou, Jian Su, Zhen Wang, Chong-Rui Xu, Yi-Sheng Huang, Bin-Chao Wang, Xue-Ning Yang, Wen-Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Ben-Yuan Jiang, Song Dong, Yi-Long Wu, Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer Lung Cancer. ,vol. 79, pp. 33- 39 ,(2013) , 10.1016/J.LUNGCAN.2012.09.016
F. Barlesi, H. Blons, M. Beau-Faller, I. Rouquette, L. Ouafik, J. Mosser, J.P. Merlio, P.P. Bringuier, P. Jonveaux, C. Le Marechal, M. Denis, F. Penault-Llorca, D. Debieuvre, J.C. Soria, J. Cadranel, J. Mazieres, P. Missy, F. Morin, F. Nowak, G. Zalcman, Biomarqueurs France : résultats de l’analyse en routine de EGFR, HER2, KRAS, BRAF, PI3K, et ALK sur 10 000 patients (pts) atteints de cancer bronchique non à petites cellules (CBNPC) Revue Des Maladies Respiratoires. ,vol. 31, ,(2014) , 10.1016/J.RMR.2013.10.041
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Hye-Ryoun Kim, Jae Chol Lee, Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jeong-Seon Ryu, Seung Hoon Jang, Ji Woong Son, Jeong Eun Lee, Sun Young Kim, Hee Joung Kim, Kye Young Lee, Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment Lung Cancer. ,vol. 83, pp. 252- 258 ,(2014) , 10.1016/J.LUNGCAN.2013.11.008
Andrew J. Weickhardt, Benjamin Scheier, Joseph Malachy Burke, Gregory Gan, Xian Lu, Paul A. Bunn, Dara L. Aisner, Laurie E. Gaspar, Brian D. Kavanagh, Robert C. Doebele, D. Ross Camidge, Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. 1807- 1814 ,(2012) , 10.1097/JTO.0B013E3182745948
Kenichi Nishie, Tomoya Kawaguchi, Akihiro Tamiya, Tomoyasu Mimori, Naoko Takeuchi, Yoshinobu Matsuda, Naoki Omachi, Kazuhiro Asami, Kyoichi Okishio, Shinji Atagi, Tomohisa Okuma, Akihito Kubo, Yoshihito Maruyama, Shinzoh Kudoh, Minoru Takada, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations Journal of Thoracic Oncology. ,vol. 7, pp. 1722- 1727 ,(2012) , 10.1097/JTO.0B013E31826913F7